Sunday, May 4, 2008

MA Life Sciences Innovation Day - June 3, 2008

I wanted to update you on what I believe will be the most important Lifesciences event for entrepreneurs and innovators in MA this year. This event, titled Massachusetts Lifesciences Innovation Day on Tuesday, June 3, 2008 at the Sheraton, Boston. This event is going to be a flagship event for showcasing and celebrating research, innovation and entrepreneurship in MA in biotech, medtech and diagnostics. (see highlights below). This event is a first-of-its-kind because all the organizations (MBC, MassMedic, TiE Boston and Mass Tech Transfer Center) in MA in Life Sciences are involved, along with all major universities.

Selected Highlights
• Craig Mello, Nobel Laureate 2006 for the discovery of RNA interference
• Philip A Sharp, Nobel Laureate 1993 and Co-Founder of Biogen
• Josh Boger, CEO Vertex Pharmaceuticals
• James Collins, Professor of Biomedical Engineering, Boston University and McArthur Fellowship Recipient
• Amar Sawhney, Founder & former CEO, Confluent Surgical, CEO, I-Therapeutix
• Christoph Westphal, CEO, Sirtris Pharmaceuticals, Former CEO, Momenta Pharmaceuticals
• Alan Crane, CEO Tempo Pharmaceuticals and former CEO, Momenta Pharmaceuticals
• Ganesh Venkatraman, Founder and SVP, Momenta Pharmaceuticals
• 10 thought leaders, innovators and successful entrepreneurs
• An Innovator’s Marketplace – everything you need to start a company
• Renowned Futurist Panel looking at the next 30 years
• Showcase of research at MA laboratories
• Live panel evaluations of new ideas
• Several networking sessions

MALSI Day Advisory Board

• Mara Aspinall, President, Genzyme Genetics
• John Brooks, Founder, Prism VentureWorks
• Robert Creeden, Partners Venture Fund
• Robert Coughlin, President, Mass Biotech Council
• Michael Greeley, Managing Partner, Flybridge Ventures
• Rainer Fuchs, Vice President & Head of Incubator, Biogen Idec
• P Laxminarain, President, Codman/DePuy; Johnson & Johnson
• Thomas Sommer, President, MassMedic
• Amar Sawhney, Founder, Confluent and CEO, I-Therapeutix

No comments: